Sometimes companies move fast and break things. Sometimes they move fast and break themselves. Hims & Hers Health, Inc. (HIMS) appears to be learning this lesson the hard way as the telehealth company finds itself under siege from federal regulators, the Department of Justice, and a pharmaceutical giant with very expensive lawyers.

The stock collapsed to new 52-week lows on Monday as investors processed what can only be described as a worst-case scenario playing out in real time.

The FDA and DOJ Come Knocking

The trouble started when Hims made an ambitious move: launching a compounded oral semaglutide pill, essentially a copycat of Novo Nordisk A/S's (NVO) newly approved oral Wegovy. The federal response was immediate and unambiguous.

Last Friday, the FDA announced "decisive steps" to restrict compounding pharmacies from mass-marketing GLP-1 ingredients. Commissioner Marty Makary didn't mince words, explicitly warning against illegal copycat drugs that haven't undergone the agency's gold-standard review process.

Then came the bigger hammer: the Department of Health and Human Services General Counsel referred Hims & Hers to the Department of Justice for potential violations of the Food, Drug and Cosmetic Act. That's the kind of referral that gets a company's legal team working through the weekend.

Facing this regulatory firestorm, Hims executed a swift retreat. On Saturday, just 48 hours after launching the oral pill, the company announced it would stop offering the product entirely.

Novo Nordisk Launches Patent Offensive

If the FDA situation wasn't enough, Monday brought a fresh crisis. Novo Nordisk announced it had filed a major patent infringement lawsuit against Hims & Hers, and this one has far broader implications.

Novo claims Hims is infringing on U.S. Patent 8,129,343, which protects semaglutide through 2032. Here's the critical difference: while the FDA crackdown focused on the new oral pill, Novo's lawsuit targets Hims' entire GLP-1 business, including its widely sold injectable compounded semaglutide.

The pharmaceutical giant is seeking a permanent injunction. If Novo succeeds, the lawsuit could eliminate a segment estimated to represent $800 million in projected 2025 revenue for Hims & Hers. That's not a rounding error.

Investors Head for the Exits

The market's reaction has been brutal. Investors are reassessing whether Hims' growth story can survive without its most lucrative new product line.

Multiple analysts slashed price targets on HIMS, with analysts at Leerink Partners noting that weight loss accounts for roughly 25% to 30% of the company's EBITDA. The stock has shed over 40% of its value in just days.

Yes, Hims remains profitable in other segments like hair loss and sexual health. But the legal uncertainty has transformed HIMS into a high-risk proposition, and investors are acting accordingly. More than four times the stock's average volume changed hands before noon on Monday as shareholders rushed to de-risk.

The company is now fighting for its legal right to sell products that were supposed to drive its next phase of growth. With federal regulators circling and a well-funded pharmaceutical company swinging patent claims, Hims & Hers faces a battle on multiple fronts simultaneously.

HIMS Price Action: According to market data, Hims & Hers Health shares were down 20.10% at $18.39 at the time of publication on Monday.